Xospata TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: gilteritinib
Pack: Xospata 40 mg tablet, 84, blister pack
Brand name
(ARTG)
: XOSPATA gilteritinib (as fumarate) 40 mg film-coated tablet blister packDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, film coated
- Oral
- Round, light yellow film-coated tablet, debossed with the company logo and 235 on the same side
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Store in Original Container
- Shelf lifetime is 4 Years.
Do I need a prescription ?
(ARTG)
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient gilteritinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
